Posted by Michael Wonder on 20 Jul 2018
Novartis joins Pfizer in holding line on drug prices in U.S.
18 July 2018 - Swiss drug maker says cost of drugs must relate to value.
Swiss drugmaker Novartis is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer to delay planned increases for some medicines.
Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday. The company wants the cost of its medicines to be “reasonable” and “defensible” and to reflect their value for patients, he said.
